Related Experiment Video
Updated: Aug 13, 2026
09:27
Generation of Fluorescent Protein Fusions in Candida Species
Published on: March 4, 2017
New agents for invasive mycoses in children
Charalampos Antachopoulos1, Thomas J Walsh
1Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
Current Opinion in Pediatrics
|January 22, 2005
Summary
New antifungal drugs show promise for immunocompromised children but require more pediatric studies. Combination and immunomodulation therapies are also explored for better outcomes in invasive fungal infections.
Area of Science:
- Pediatric Infectious Diseases
- Mycology
- Pharmacology
Background:
- Invasive fungal infections pose significant risks in immunocompromised children.
- Echinocandins and second-generation triazoles represent novel antifungal agents.
Purpose of the Study:
- To review new antifungal agents and alternative therapies for pediatric invasive fungal infections.
- To summarize current clinical data on these agents in children.
Main Methods:
- Literature review of novel antifungal agents.
- Analysis of clinical data on efficacy and safety in pediatric populations.
- Exploration of combination and immunomodulation strategies.
Main Results:
- Novel agents like echinocandins and triazoles demonstrate efficacy against common fungal pathogens.
- These agents are generally well-tolerated and effective in salvage and first-line therapy.
- Limited pediatric-specific pharmacokinetic and efficacy data exist for new antifungals.
Conclusions:
- While new antifungals offer improvements, response rates remain suboptimal.
- Further research is needed for new antifungal compounds and alternative strategies in pediatric patients.
- Well-designed clinical studies are crucial for advancing pediatric antifungal treatment.
Related Concept Videos
01:23Skin Diseases and Disorders
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...